Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutics development for spinal muscular atrophy.

Charlotte J Sumner1

  • 1Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA.

Neurorx : the Journal of the American Society for Experimental Neurotherapeutics
|March 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A p53-ΔNp73 signaling axis drives selective motor neuron degeneration in spinal muscular atrophy.

bioRxiv : the preprint server for biology·2026
Same author

A standardized framework resolves ambiguity in motor neuron loss across neurodegenerative diseases.

bioRxiv : the preprint server for biology·2026
Same author

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Nature medicine·2026
Same author

KIF5A downregulation in spinal muscular atrophy links axonal regeneration defects with ALS.

JCI insight·2026
Same author

Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients.

Acta neuropathologica communications·2026
Same author

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Nature medicine·2026

Spinal muscular atrophy (SMA) is a severe genetic motor neuron disease. Increasing the expression of the SMN2 gene may offer a therapeutic benefit for patients with SMA.

Area of Science:

  • Genetics
  • Neurology
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is a leading inherited cause of infant mortality.
  • SMA results from mutations in the survival motor neuron gene 1 (SMN1), leading to insufficient SMN protein.
  • The SMN protein is crucial for motor neuron function, including spliceosome assembly and mRNA transport.

Purpose of the Study:

  • To explore the potential of increasing SMN expression as a therapeutic strategy for SMA.
  • To review current and emerging therapeutic approaches for SMA.
  • To highlight challenges in clinical trials for SMA.

Main Methods:

  • Analysis of the correlation between SMN2 gene copy number and SMA disease severity.
  • Evaluation of SMN2 gene copy number effects in transgenic mouse models.

Related Experiment Videos

  • Review of ongoing and proposed therapeutic strategies for SMA.

    • Main Results:

    • SMA disease severity inversely correlates with SMN2 gene copy number in patients.
    • Increased SMN2 gene copy number can prevent the SMA phenotype in mouse models.
    • Multiple therapeutic strategies targeting SMN expression and protein levels are under investigation.

    Conclusions:

    • Increasing SMN levels holds promise for treating SMA.
    • Current therapeutic strategies include SMN2 gene expression induction, splicing modulation, protein stabilization, neuroprotection, and gene replacement.
    • Clinical trials for SMA require development of effective outcome measures and biomarkers.